Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ.
about
New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney DiseasePodocytesTherapeutic targeting of aldosterone: a novel approach to the treatment of glomerular diseaseThe podocyte power-plant disaster and its contribution to glomerulopathy.Pharmacological targeting of GSK3β confers protection against podocytopathy and proteinuria by desensitizing mitochondrial permeability transition.cAMP signaling prevents podocyte apoptosis via activation of protein kinase A and mitochondrial fusion.Loss of Krüppel-like factor 6 cripples podocyte mitochondrial function.Huaier Cream Protects against Adriamycin-Induced Nephropathy by Restoring Mitochondrial Function via PGC-1α UpregulationProgress in pathogenesis of proteinuria.Rotenone Attenuates Renal Injury in Aldosterone-Infused Rats by Inhibiting Oxidative Stress, Mitochondrial Dysfunction, and Inflammasome Activation.The redox sensitive glycogen synthase kinase 3β suppresses the self-protective antioxidant response in podocytes upon oxidative glomerular injury.Ginsenoside Rg1 protects mouse podocytes from aldosterone-induced injury in vitro.Redox-sensitive glycogen synthase kinase 3β-directed control of mitochondrial permeability transition: rheostatic regulation of acute kidney injury.Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy.Diabetes-Induced Reactive Oxygen Species: Mechanism of Their Generation and Role in Renal InjuryThe renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.Mineralocorticoid receptor activation as an etiological factor in kidney diseases.Association of peroxisome proliferator-activated receptors/retinoic acid receptors with renal diseases.Mitochondrial dysfunction in the pathophysiology of renal diseases.Fetal programming of chronic kidney disease: the role of maternal smoking, mitochondrial dysfunction, and epigenetic modfification.NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury.MicroRNA-30e targets BNIP3L to protect against aldosterone-induced podocyte apoptosis and mitochondrial dysfunction.Peroxisome proliferator activating receptor-γ and the podocyte.The metabolic syndrome and chronic kidney disease.Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats.Dahuang Fuzi Decoction Attenuates Renal Fibrosis and Ameliorates Mitochondrial Dysfunction in Chronic Aristolochic Acid Nephropathy.Peroxisome proliferator-activated receptor γ Pro12Ala polymorphism decrease the risk of diabetic nephropathy in type 2 diabetes: a meta analysis.Mitochondrial dysfunction is an early event in aldosterone-induced podocyte injury.Reactive oxygen species-initiated autophagy opposes aldosterone-induced podocyte injury.Grape seed procyanidin B2 protects podocytes from high glucose-induced mitochondrial dysfunction and apoptosis via the AMPK-SIRT1-PGC-1α axis in vitro.The roles of oxidative stress, endoplasmic reticulum stress, and autophagy in aldosterone/mineralocorticoid receptor-induced podocyte injury.Hyperoside alleviates adriamycin-induced podocyte injury via inhibiting mitochondrial fission.Total flavones of Abelmoschus manihot improve diabetic nephropathy by inhibiting the iRhom2/TACE signalling pathway activity in rats.Urinary mitochondrial DNA level is an indicator of intra-renal mitochondrial depletion and renal scarring in diabetic nephropathy.Sildenafil Prevents Podocyte Injury via PPAR-γ-Mediated TRPC6 Inhibition.The potential signaling pathway between peroxisome proliferator-activated receptor gamma and retinoic acid receptor alpha in renal interstitial fibrosis disease.Contributions of endoplasmic reticulum stress and reactive oxygen species to renal injury in aldosterone/salt-induced rats.Aldosterone Impairs Mitochondrial Function in Human Cardiac Fibroblasts via A-Kinase Anchor Protein 12.
P2860
Q26739475-E0F94FDD-E0FF-4F40-B63D-1EA2970446EBQ26766118-9733500E-5772-4B4B-BCD9-DAC7BF0B8D78Q26996385-4AB92FCA-2861-46F7-BF8C-2555CB6BF54AQ34699773-88087C02-A0BB-41C7-BD9D-464A6CB49255Q34994550-DDDFA27C-4FE4-4D7C-A9C0-2482E8E7C870Q35124052-FD73BFCA-6428-434D-A5A4-DCF87E8035BFQ35183931-F7A08BB9-5522-4BD7-905E-38B42B0C7947Q35226985-8E66269E-548C-49D1-A340-1F5F20D29C4CQ36011008-72E02C41-830A-4D09-A766-8864E057E268Q36187559-10C72886-A312-48B2-BAFC-AF40E4B3FB4FQ36545412-2A426B05-1DD5-4965-B973-3A99E4B9BBFCQ36745190-7FDF8EFB-E9AD-43FE-83B4-7D368B52CE93Q37385047-16DC9160-632A-43E1-9637-E35F903C0A91Q37580301-7391761E-6CD0-47DE-B64B-00C5CA72B285Q37590946-CE347DE2-FBDB-4805-83B4-CE436E39E505Q37597721-294D2CB0-473B-42D1-9A9C-5F458F2044F7Q37997004-3054603C-916D-4AA6-906B-F2722137A091Q38072297-4B8BEB32-8131-4AA0-AE7D-7024FC3B5100Q38119861-3D6031DA-5D4C-4AF6-92DC-5742860F7D54Q38139624-6799ED80-66AC-4125-AC10-B1473F4DF527Q38168664-E87A6009-3AF6-4977-B436-3E4956AC1FC2Q38345872-96DCB837-0AC5-4F97-9222-EA3750087852Q38722963-4F3935B1-1274-4602-8CE2-A7C89159FD24Q38726222-B70D54E0-FF44-479B-8824-EC6D73CD01FDQ38815188-00027FCB-87FB-4C6F-AF9C-126711BE8384Q39056509-9C685F66-2889-4572-8888-158055470879Q41437002-464415D4-F97E-45DB-91D9-F9193A2C9C38Q42292920-E1F5A046-BC69-48E3-9F53-BD3F88D81150Q42364753-86200B8A-A6EF-4961-B717-DAEBF9E934DAQ44067417-99A2ADE1-163B-4CBC-93E9-7DD74150BF40Q46611165-7E281850-228D-446B-B410-BDABA0C72723Q46626225-B1544A17-919D-430A-B235-9FF5477C2564Q46662837-2CC964A2-4A16-4671-BED6-89D574A4C833Q47148010-84DC4B8A-EA35-491B-B262-AFB11B37E675Q49995821-1C03AC02-64A4-4662-8F68-01B68BB20DAEQ50192998-6324CC36-A452-4F6F-91EA-B4B5113B74EFQ51299126-E1F6C8F9-CE19-46E8-BF3E-8BFE7287A4FCQ53007399-1CCACBE6-24FD-4F84-ABCF-996EFCE251E2Q53061760-4B33DFB5-EF2C-45B2-A3A9-7920C0AA51DEQ54979932-1B8091FD-08F1-4143-B134-0D4C2E3B56F8
P2860
Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@ast
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@en
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@nl
type
label
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@ast
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@en
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@nl
prefLabel
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@ast
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@en
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@nl
P2093
P2860
P1476
Mitochondrial dysfunction medi ...... a therapeutic target of PPARγ.
@en
P2093
Aihua Zhang
Bicheng Liu
Chunhua Zhu
Guixia Ding
Ronghua Chen
Songming Huang
Tianxin Yang
Yanggang Yuan
P2860
P304
P356
10.1016/J.AJPATH.2011.01.029
P407
P577
2011-05-01T00:00:00Z